Advertisement

Topics

PubMed Journals Articles About "Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia" RSS

13:43 EDT 23rd July 2018 | BioPortfolio

Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia articles that have been published worldwide.

More Information about "Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia" on BioPortfolio

We have published hundreds of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia news stories on BioPortfolio along with dozens of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Clinical Trials and PubMed Articles about Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Companies in our database. You can also find out about relevant Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Drugs and Medications on this site too.

Showing "genehmigt erweiterte Indikation Novartis Krebsmittel Zykadia" PubMed Articles, all 5

NVP-BHG712: Effects of regioisomers on the affinity and selectivity towards the EPHrin family.

EPH receptors are transmembrane receptor tyrosine kinases. Their extracellular domains bind specifically to ephrin A/B ligands, and this binding modulates the intracellular kinase activity. EPHs are key players in bidirectional intercellular signaling, controlling cell morphology, adhesion and migration. They are increasingly recognized as cancer drug targets. We analyzed the binding of the Novartis inhibitor NVP-BHG712 (NVP) to EPHA2 and EPHB4. Unexpectedly, all tested commercially available NVP samples tu...


How Often Do Safety Signals Occur by Chance in First-in-Human Trials?

Clinicians working on first-in-human clinical studies need to be able to judge whether safety signals observed on an investigational drug were more likely to have occurred by chance or to have been caused by the drug. We retrospectively reviewed 84 Novartis studies including 1,234 healthy volunteers receiving placebo to determine the expected incidence of changes in commonly measured laboratory parameters and vital signs, in the absence of any active agent. We calculated the frequency of random incidence of...

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescarta of KITE Pharma, the first CAR T cell therapy products have been approved. Promising clinical outcomes have yet been tempered by the fact that many therapies may be prohibitively expensive to manufacture. The process is not yet defined, far from being standardised and often requires extensive manual handling ...


Continuous manufacturing of co-crystals: challenges and prospects.

The last decade has witnessed extensive growth in the field of co-crystallization for mitigating the solubility and dissolution-related issues of poorly soluble drugs. This is largely because co-crystals can modify the physicochemical properties of drugs without any covalent modification in the drug molecules. The US Food and Drug Administration (FDA) now considers drug products that are designed to contain a new co-crystal, analogous to new polymorph of the active pharmaceutical ingredient (API). This posi...

Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine.

When faced with a diagnosis of multiple sclerosis (MS), patients often turn to the Internet and social media to find support groups, read about the experiences of other people affected by MS and seek their advice, and research their condition and treatment options to discuss with their healthcare professionals (HCPs). Here, we examine the use of social media and the Internet among patients with MS, considering its impact on patient empowerment and patient participation in treatment decision-making and MS re...


Advertisement
Quick Search
Advertisement
Advertisement